Pfizer develops, manufactures, and sells prescription drugs and vaccines to patients worldwide, distributed through hospitals, pharmacies, and healthcare systems. Key products include the Prevnar pneumococcal vaccine, blood thinner Eliquis (co-marketed with Bristol-Myers Squibb), and heart drug Vyndamax. Revenue comes from product sales across more than 100 countries, split roughly 60% U.S. and 40% international, with emerging markets making up a meaningful share of the latter.
Employees75,000IPOJun 22, 1951SIC2834HQ66 Hudson Boulevard East, New York, NY, USA, 10001-2192
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
73.2%
Operating Margin
26.7%
EBITDA Margin
21.2%
Net Margin
6.8%
OCF Margin
21.0%
FCF Margin
17.3%
Returns on Capital
ROE
4.9%
ROA
2.1%
ROIC
9.0%
ROCE
4.1%
ROC (Greenblatt)
36.2%
3Y ROIIC
−121.2%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
38.92
Forward P/E
9.92
P/E ex-NRI
9.65
Shiller P/E (CAPE)
10.49
Cash Flow Multiples
P/FCF
15.42
P/OCF
12.61
P/Owner Earnings
42.88
FCF Yield
6.51%
Enterprise Value Multiples
EV / EBIT
31.86
EV / Forward EBIT
11.59
EV / EBITDA
16.31
EV / Forward EBITDA
9.83
EV / Revenue
3.45
EV / Forward Revenue
3.54
Asset / Sales
P/S
2.63
P/B
1.98
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
5.84%
Forward Dividend Yield
5.84%
3Y Dividend Growth
2.4%
Payout Ratio
0.56
5Y Yield on Cost
7.30%
Buybacks & Dilution
3Y Buyback Ratio
−0.40%
5Y Share Change
1.4%
Combined
Shareholder Yield
5.96%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.74
Gross Debt / EBITDA
4.68
Cash / Debt
0.19
Equity / Assets
0.42
Coverage
Interest Coverage
6.31
Short-Term Liquidity
Current Ratio
1.27
Quick Ratio
0.96
Cash Ratio
0.36
Composite Scores
Piotroski F-Score
7
Altman Z-Score
2.05
Split History
Date
Split
1999-07-01
3:1
1997-07-01
2:1
1995-07-03
2:1
1991-04-01
2:1
1983-07-01
2:1
1970-05-26
3:1
Ex-date
Amount
Pay date
2026-05-08
$0.43
2026-06-12
2026-01-23
$0.43
2026-03-06
2025-11-07
$0.43
2025-12-01
2025-07-25
$0.43
2025-09-02
2025-05-09
$0.43
2025-06-13
2025-01-24
$0.43
2025-03-07
2024-11-08
$0.42
2024-12-02
2024-07-26
$0.42
2024-09-03
2024-05-09
$0.42
2024-06-14
2024-01-25
$0.42
2024-03-01
10 of 162
View allDate
Transcript
Type
2026-08-04
Q2 2026 Pfizer Inc Earnings Call Transcript
Earnings Call
2026-06-08
Pfizer Inc at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-06-06
Pfizer Inc Pflash Live from ADA A Spotlight on Obesity Transcript
Analyst/Investor Call
2026-06-03
Pfizer Inc at Jefferies Global Healthcare Conference in New York Transcript
Conference Presentations
2026-05-05
Q1 2026 Pfizer Inc Earnings Call Transcript
Earnings Call
2026-03-02
Pfizer Inc at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-03
Q4 2025 Pfizer Inc Earnings Call Transcript
Earnings Call
2026-01-12
Pfizer Inc at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-16
Pfizer Inc to Host Full-Year 2026 Guidance Call Transcript
Guidance Call
2025-11-04
Q3 2025 Pfizer Inc Earnings Call Transcript
Earnings Call
10 of 122
5-Step DuPont Analysis
ROE %
4.98%
×
×
Net Margin %
6.80%
×
×
Operating Margin %
26.72%
Operating Income
$17.02B
÷
Revenue
$63.70B
×
Tax Burden
1.0292
Net Income
$4.33B
÷
Pretax Income
$4.21B
×
Interest Burden
0.2473
Pretax Income
$4.21B
÷
Operating Income
$17.02B
×
Asset Turnover
0.31
÷
Revenue
$63.70B
÷
Average Total Assets
$203.61B
Begin Total Assets
$206.09B
End Total Assets
$201.13B
×
Equity Multiplier
2.34
÷
Avg Total Assets
$203.61B
÷
Avg Stockholders Equity
$86.94B
Begin Equity
$88.69B
End Equity
$85.19B
Top institutional holders
Q2 2026| Holder | Shares | % Owned | Chg. shares | |
|---|---|---|---|---|
| BlackRock, Inc. | 529.7M | 9.31% | +31.4M | $12.75B |
| VANGUARD CAPITAL MANAGEMENT LLC | 372.1M | 6.54% | +2.7M | $8.96B |
| STATE STREET CORP | 307.1M | 5.40% | +5.5M | $7.39B |
| GEODE CAPITAL MANAGEMENT, LLC | 135.3M | 2.38% | +1.7M | $3.25B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 119.2M | 2.10% | +2.5M | $2.87B |
| Fisher Asset Management, LLC | 109.1M | 1.92% | +4.1M | $2.63B |
| MORGAN STANLEY | 96.3M | 1.69% | +3.7M | $2.32B |
| NORGES BANK | 61.5M | 1.08% | new | $1.48B |
| NORTHERN TRUST CORP | 59.1M | 1.04% | -2.9M | $1.42B |
| Bank of New York Mellon Corp | 57.9M | 1.02% | +4.0M | $1.39B |
10 of 2,856
View allTop insider holdings
as reported| Insider | Shares held | % Owned | |
|---|---|---|---|
| BOURLA ALBERTOfficer | 429.2K | 0.0075% | $12.69M |
| SUSMAN SALLYOfficer | 168.9K | 0.0030% | $5.00M |
| LANKLER DOUGLAS MOfficer | 163.2K | 0.0029% | $4.83M |
| BOSHOFF CHRISTOFFELOfficer | 161.4K | 0.0028% | $4.77M |
| McDermott MichaelOfficer | 74.3K | 0.0013% | $2.20M |
| BLAYLOCK RONALD EDirector | 71.7K | 0.0013% | $2.12M |
| Fonseca LidiaOfficer | 46.5K | 0.0008% | $1.37M |
| Buckley Mortimer JDirector | 37.6K | 0.0007% | $1.11M |
| DAMICO JENNIFER B.Officer | 28.6K | 0.0005% | $846.3K |
| SAHNI PAYALOfficer | 27.7K | 0.0005% | $818.4K |
10 of 11
View allRecent insider activity
through Aug 12, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| BOURLA ALBERTOfficer | Open-Market or Private Purchase | +38.0K | $1.00M | Aug 12, 2026 |
| DAMICO JENNIFER B.Officer | Open-Market or Private Sale | -3.3K | $83.3K | Aug 5, 2026 |
| BLAYLOCK RONALD EDirector | Open-Market or Private Purchase | +39.2K | $998.8K | Aug 5, 2026 |
| Buckley Mortimer JDirector | Open-Market or Private Purchase | +37.6K | $960.4K | Aug 5, 2026 |
| DAMICO JENNIFER B.Officer | Open-Market or Private Sale | -2.0K | $51.4K | Jun 9, 2026 |
| DAMICO JENNIFER B.Officer | Tax Withholding | -826 | $22.0K | Mar 4, 2026 |
| DAMICO JENNIFER B.Officer | Grant/Award (Rule 16b-3(d)) | +16.3K | $0 | Mar 3, 2026 |
| DAMICO JENNIFER B.Officer | Grant/Award (Rule 16b-3(d)) | +5.4K | $0 | Mar 3, 2026 |
| DAMICO JENNIFER B.Officer | Tax Withholding | -655 | $18.1K | Feb 27, 2026 |
| McDermott MichaelOfficer | Tax Withholding | -3.5K | $94.9K | Feb 26, 2026 |
10 of 2,478
View all